Picture of Corcept Therapeutics Incorporated logo

CORT — Corcept Therapeutics Incorporated News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Corcept Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

* Corcept Therapeutics Inc  CORT.OQ  reported quarterly
adjusted
earnings of 25 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of 14 cents.  The mean expectation of five analysts
for the quarter was for earnings of 22 cents per share. Wall
Street expected results to range from 19 cents to 26 cents per
share.
    * Revenue rose 39% to $146.81 million from a year ago;
analysts
expected $141.20 million. 
    * Corcept Therapeutics Inc's reported EPS for the quarter
was 25
cents​.
    * The company reported quarterly net income of $27.76
million.
    * Corcept Therapeutics Inc shares had fallen by 7.4% this
quarter and lost 28.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 4.3%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Corcept
Therapeutics Inc is $38.00 
This summary was machine generated from LSEG data May 2 at 03:13
a.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      0.22           0.25           Beat
 Dec. 31 2023      0.26           0.28           Beat
 Sep. 30 2023      0.22           0.28           Beat
 Jun. 30 2023      0.15           0.25           Beat

Recent news on Corcept Therapeutics Incorporated

See all news